Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Friday, May 16th, 2008.
<p><strong>MicroRNAs as Potential Biomarkers — for Lung Cancer Diagnosis and Identification of Tumor Origin in Patients With Cancer of Unknown Primary (CUP) MicroRNAs Objectively Identify Cancer Types With High Sensitivity and Specificity and Could Revolutionize Diagnosis and Treatment of Cancer</strong></p>
<p><strong>Jersey City, NJ </strong> - Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in
the development of microRNA-based diagnostics and therapeutics, today
announced that it will present multiple posters at the upcoming ASCO annual
meeting in Chicago. The company also has three publication only abstracts
available on ASCO’s website. The event will take place from May 30 to June 3
at the McCormick Place, Chicago, Illinois. </p>
<h2>Presented posters: </h2>
<ol>
<li><strong>"MicroRNA signature identifies tissue origin of primary and metastatic
tumors"</strong>; <br />
<em>Tuesday, June 03, 8:00AM - 12:00PM; Hall S102a, abstract # 11028. </em><br />
Each year approximately 70,000 patients in the United States are
diagnosed with cancer of unknown primary (CUP). Accurately identifying the
origin of a metastasis can be critical in guiding treatment decisions.
Rosetta Genomics’ scientists have designed a classifier which assigns a
primary site to a cancer sample based on the microRNA expression in the
sample. The overall sensitivity of this classifier is approximately 85%, with
two-thirds of the samples being classified with high-confidence, reaching
accuracy exceeding 90% and specificity of 99%. </li>
<li><strong>"Differential microRNA expression in pleural mesothelioma:
Implications for early detection and prognostication"</strong>; <br />
<em>Tuesday, June 03;
8:00AM - 12:00PM; Hall S102a; abstract # 11027. </em><br />
Malignant mesothelioma (MM)
is an asbestos induced pleural neoplasm with a median survival (MS) of 12
months, and relatively little is known about the molecular events that lead
to the development of this highly aggressive disease. Using Rosetta Genomics’
unique microRNA platform, Dr. Harvey Pass, NYU School of Medicine, examines
whether there are distinct mir profiles between MM and normal mesothelium,
and whether mirs are associated with demographic/prognostic features in MM
patients. </li>
<li><strong>"MicroRNAs as powerful diagnostic tools for the differential diagnosis
of lung tumors"</strong>; <br />
<em>Sunday, June 01; 8:00AM - 12:00PM; Hall S A1; abstract #
11112. </em><br />
Lung cancer is a heterogeneous disease with many histological
subtypes, further complicated by the frequent occurrence of lung metastases
from various tumor origins. Therefore, determining the correct diagnosis of
any lung tumor often poses a difficult diagnostic challenge that may have
very significant therapeutic implications. This poster will detail the use of
microRNAs for differentiating between different primary lung tumors and
metastases to the lung. </li>
<li><strong>"MicroRNA expression profile identifies origin of tumors in the
liver"</strong>; <br />
<em>Tuesday, June 03; 8:00AM - 12:00PM; Hall S102a; abstract # 11026. </em><br />
The
distinction of liver metastasis from hepatocellular carcinoma (HCC) and
determining its tissue origin is a frequent problem in oncology, especially
since liver metastases, and particularly adenocarcinoma, may mimic the
morphology and immunoexpression of hepatocellular carcinoma. Such distinction
has significant therapeutic and prognostic implications. In the present
study, Rosetta Genomics and collaborators use microRNAs as biomarkers for
tissue identification to distinguish between HCC and metastatic tumors in the
liver. </li>
</ol>
<h2>Publication only abstracts: </h2>
<ol style=”counter-reset:item 4″>
<li><strong>"MicroRNAs as specific biomarkers for distinguishing between primary
and metastatic brain tumors" </strong><br />
A recurring challenge for brain pathologists is
to diagnose whether a brain malignancy is a primary tumor or a metastasis
from some other origin. The accurate diagnosis of brain malignancies is
essential for selection of proper treatment. In this study, Rosetta Genomics’
scientists examine whether the specific expression of microRNAs may be
utilized in the identification and diagnosis of brain malignancies. </li>
<li><strong>"MicroRNAs as a diagnostic tool for differentiating squamous cell lung
cancer from other non small cell lung cancers" </strong><br />
Lung cancer is the leading
cause of cancer-related death among men and women. Of all lung cancer cases,
80% are non-small-cell lung cancer (NSCLC) which includes adenocarcinoma,
squamous-cell carcinoma and large-cell carcinoma. Careful diagnosis of lung
cancer patients before treatment with angiogenesis inhibitor drugs is
critical. Bevacizumab, a therapy for non-squamous NSCLC, includes a warning
about potential higher rates of severe or fatal hemorrhage in patients with
squamous NSCLC histology. </li>
<li><strong>"Differential diagnosis of mesothelioma using a microRNA assay"
</strong><br />
Malignant mesothelioma is an aggressive pleural neoplasm primarily induced by
asbestos exposure. Mesothelioma in the lung pleural is difficult to
differentiate from other tumors in the lung pleura, such as primary lung
adenocarcinoma protruding into the pleural space and metastatic
adenocarcinoma from other tissues. Rosetta Genomics’ scientists investigated
the microRNA expression profiles of lung mesothelioma and adenocarcinoma, and
the potential of microRNAs as clinical biomarkers that distinguish between
mesothelioma and adenocarcinoma. </li>
</ol>
<h3>About MicroRNA </h3>
<p>MicroRNAs (miRNAs) are recently discovered, naturally occurring, small
RNAs that act as master regulators and have the potential to form the basis
for a new class of diagnostics and therapeutics. Since many diseases are
caused by the abnormal activity of proteins, the ability to selectively
regulate protein activity through microRNAs could provide the means to treat
a wide range of human diseases. In addition, microRNAs have been shown to
have different expression in various pathological conditions. As a result,
these differences may provide for a novel diagnostic strategy for many
diseases. </p>
<h3>About Rosetta Genomics </h3>
<p>Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA.
Founded in 2000, the company’s integrative research platform combining
bioinformatics and state-of-the-art laboratory processes has led to the
discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong IP position and proprietary platform technologies,
Rosetta Genomics is working on the application of these technologies in the
development of a full range of microRNA-based diagnostic and therapeutic
tools, focusing primarily on cancer and various women’s health indications.
The company expects that the first microRNA diagnostic tests applying its
technology will be launched by licensed clinical laboratories in the United
States in 2008.</p>
« Mesothelioma News Main Page.
You can follow any responses to this entry through the RSS 2.0 feed.
You can skip to the end and leave a response. Pinging is currently not allowed.